Effect of Cilostazol, a Novel Anti-Platelet Drug, on Restenosis After Percutaneous Transluminal Coronary Angioplasty

概要

論文の詳細を見る
The possible preventive effect of cilostazol, a novel anti-platelet drug, on restenosis after successful percutaneous transluminal coronary angioplasty(PTCA)was examined. One hundred and two consecutive patients, who underwent successful PTCA, were followed for 3 to 6 months. To prevent restenosis, 46 patients(60 PTCA sites)were treated with cilostazol alone(200 mg/day)(cilostazol group)and the remaining 56(61 PTCA sites)were treated with other anti-platelet drugs and/or warfarin potassium(control group). Restenosis was defined as a more than 50% loss of the initial gain of the coronary diameter achieved by PTCA. Cilostazol did not significantly reduce the patient or lesion restenosis rate ; the patient restenosis rate was 32% in the control group and 22% in the cilostazol group(P=0.24), and the lesion restenosis rate was 30% in the control group and 23% in the cilostazol group(P=0.44). However, the lesion non-progression rate, which was defined as the incidence of lesions with either no change or regression of coronary stenosis at the PTCA site, was significantly greater with cilostazol(37%)than in the control group(16%)(p<0.05). Although cilostazol failed to show a significant reduction in restenosis after PTCA, the present results suggest that a further trial with a larger number of patients is needed to confirm its usefulness.
社団法人日本循環器学会の論文
1996-03-20